Upcoming IPO: Gurugram-based pathology and imaging firm Modern Diagnostic and Research Center Limited filed its draft Red Herring Prospectus (DRHP) with Markets Regulator Securities and Exchange Board of India (Sebi) Monday, April 1.
The company started its pathology and imaging operations from New Railway Road in 1985 GurugramAnd since then, it has completed over 1.5 crore customers.
According to data collected from the official website, the company has 21 centers across the country, including 17 laboratories and 4 clinical centers, where it has conducted over 200 million tests.
Modern clinical IPO details
Modern clinical, through a book-made issue, is to raise money with the objective of Indian stock market With a new issue of a new issue of 41,00,000 or 41 lakh equity shares 10 Apis. The offer document does not include any offer-for-cell (offs) component, and the total amount of the problem is unknown in regulatory filing.
After three days of membership round, SME IPO will be listed on the Bombay Stock Exchange SME index.
Pathology and imaging firm have planned to use the funds raised from the initial public offer (IPO) Its capital expenditure (CAPEX) is required to purchase medical devices for its clinical centers and laboratories.
The company will also use income from this issue to meet the needs of working capital, and also in repayment or prior payment of some outstanding borrowings received by modern diagnostic. The remaining funds will be used to support general corporate needs.
Binea Capital Advisors Private Limited has been appointed as a book-hanging lead manager for public issues, while MUFG INTIME INTIME INDIA will be Registrar for Private Limited proposal.
According to the official press release, modern diagnostic reported net profit 5.79 crore and a revenue from operation 67.13 crore for the financial year ending 31 March 2024.
For the net profit of the company July to September quarter The financial year was at 2024-25 4.95 crores, and revenue from operation was According to the company’s data, 39.97 crores.
Disclaimer: The above views and recommendations are of individual analysts or broking companies, not Mint. We recommend investors to investigate with certified experts before taking any investment decisions.
